Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 19/20 | 0.65 |
| ▸ | KDM6B | O15054 | 8/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | KDM4A | O75164 | 2/20 | 0.52 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.52 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.48 |
| ▸ | KDM5C | P41229 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17378636 | 0.82 | KDM4C (0.89) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL17378717 | 0.82 | KDM4C (0.89) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL4754268 | 0.80 | KDM4C (0.61) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL15286471 | 0.79 | KDM4C (1.00) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL17378640 | 0.79 | KDM4C (1.00) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL15295175 | 0.77 | KDM4C (1.00) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL15295165 | 0.76 | KDM4C (1.00) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL17113083 | 0.72 | KDM4C (0.74) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL10719056 | 0.72 | KDM4C (0.77) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL15286854 | 0.72 | KDM4C (0.62) | KDM4CKDM6BKDM4EKDM4AKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015200709-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |